Motus GI Holdings, a leading medical technology company, continues its remarkable stock surge following the recent announcement of receiving clearance from the U.S. Food and Drug Administration (FDA) for the special 510(k) for technological advancements incorporated in the new Pure-Vu EVS Gastro and Gen 4 Colon system.
At the time of this publication, Motus GI Holdings Inc stock (MOTS) has witnessed a surge.
Motus GI Holdings Inc
Current Price: $0.56
Change : +0.15
Change (%): (35.85%)
Volume: 8.4M
Source: Tomorrow Events Market Data
The introduction of Pure-Vu EVS Gastro is poised to make a pivotal impact on the upper gastrointestinal (GI) market, providing access to high acuity patients suffering from upper GI bleeds—a condition with high mortality rates due to visualization challenges. Both the Pure Vu EVS Gastro and the upgraded colon version boast substantial improvements compared to previous models, with the potential to revolutionize the GI market by introducing advanced capabilities while also streamlining collaboration with commercial partners. Both products utilize the same workstation, establishing an efficient platform to enhance visualization in both the upper and lower GI tract, thereby catering to multiple indications and offering clinical benefits to patients while enhancing operational efficiencies for hospital systems.
Mark Pomeranz, Chief Executive Officer, expressed his enthusiasm over the FDA clearance, highlighting key enhancements such as a larger, more potent suction channel, improved irrigation jets, and a more compact distal tip, enabling greater flexibility during insertion and navigation. This latest version also significantly reduces the cost-of-goods by approximately 50% and slashes customer training requirements from hours to minutes. Based on positive feedback from physicians, Pomeranz anticipates a warm reception for the Upper GI indication and these enhancements within the GI community, forecasting a surge in market adoption of the Pure-Vu EVS platform.
Pomeranz further outlined the company’s plans, stating, “We look forward to initiating market introduction of the Pure-Vu EVS Gastro and Gen 4 Colon in the U.S. by the end of the year. Currently, we are planning to ramp up manufacturing supply and expect to have supply of both new products to customers in the coming months.”
The Pure-Vu EVS Gen 4 Gastro capitalizes on the success of the patented and proprietary pulsed vortex irrigation and smart sense suction utilized in the colon device, with specific enhancements tailored to target blood and blood clots in the upper GI tract.
According to iData Research Inc., Upper GI bleeds afflicted approximately 400,000 cases in the U.S. in 2019. The presence of blood and blood clots in these patients obstructs a physician’s view, complicating the identification of the bleed source. Motus GI Holdings contends that eliminating adherent blood clots from the field of view fulfills a crucial need in enabling physicians to promptly identify and treat the bleed source. Thad Wilkins, MD, et al., reported in the American Family Physician (2012) that the mortality rate for this condition can be as high as 10%.
*Past stock performance of Motus GI Holdings:*
– 5 Day: 0.00%
– 1 Month: 14.99%
– 3 Month: -12.65%
– **Year-to-Date (YTD): -33.33%
– 1 Year: -71.57%
